Solid Q1 2025 Fuels Optimism for FY25
09/05/25 -"Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of consensus. All segments and regions contributed to ..."
Pages
53
Language
English
Published on
09/05/25
You may also be interested by these reports :
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...
08/06/26
Anticipated sales are now even more skewed toward 2H, with HSD growth expected in 1H. We also record a CHF15m decrease in Building K sales in 2026, ...
04/06/26
Over the 5 days to 02-06, 18 pharma stocks out of the 23 under coverage fell. The sector performance chart is not looking good. We see an opportunity ...
01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...